BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Roche

Status: Completed

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01791140

ML25630

Details and patient eligibility

About

This observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy in elderly patients (>/= 65 years of age) with newly diagnosed metastatic colorectal cancer. Patients will be followed until disease progression, death, withdrawal of consent, discontinuation of physician-patient relationship or study closure, whichever comes first.

Enrollment: 3 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 65 years of age
• Patients with newly diagnosed metastatic colorectal cancer starting first-line treatment with Avastin in combination with fluoropyrimidine-based chemotherapy according to the approved Hungarian Summary of Product Characteristics
• Patients suitable for Avastin treatment as assessed by the treating physician

Exclusion criteria

• Any contraindications to Avastin treatment according to the Hungarian Summary of Product Characteristics

Trial design

3 participants in 1 patient group

Cohort